Table 7 Analysis of clinical and laboratorial parameters according to improvement (Group 2A) or not (Group 2B) of EQ-VAS at the end of vitamin D supplementation

BMI (kg/m²)

23.3 ± 4

23.4 ± 4

24.3 ± 5

24.3 ± 5

NS

Peripheral neuropathy yes/no (%)

(4/21)

16%

(3/22)

12%

(12/27) 30%

(8/31)

21%

NS

Basal insulin dose (IU)

36 ± 14.2

39 ± 19

35 ± 19

34 ± 19

NS

Prandial insulin dose (IU)

22.7 ± 9

21.7 ± 10

22.1 ± 13

24.4 ± 12

 < 0.05^a

25(OH)VD (ng/mL)

26.1 ± 9

62.7 ± 27

27.1 ± 9

50.3 ± 20

 < 0.001^a,b

HbA1c (%)

9.6 ± 2

9.7 ± 3

9.6 ± 2

9.8 ± 3

NS

HDL cholesterol (mg/dL)

47 ± 10

44 ± 8

48 ± 13

46 ± 12

NS

LDL cholesterol (mg/dL)

126 ± 27

122 ± 30

122 ± 43

128 ± 58

NS

Non-HDL cholesterol (mg/dL)

88 ± 28

96 ± 46

107 ± 60

118 ± 83

NS

Albuminúria (mg/24 h – Log10)

1.2 ± 0.7

0.98 ± 0.7

1.3 ± 0.8

1.4 ± 0.7

 < 0.05^b*